TECVAYLI™▼ (teclistamab)

Janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

# TECVAYLI™ (teclistamab)▼ Patient Card

**Important Safety Information for Patient Receiving TECVAYLI®(teclistamab)**

Carry this card with you at all times.
**SHOW THIS CARD** to any healthcare professional involved in your care and if you go to the hospital

This card has been reviewed and approved by The Saudi Food and Drug Authority (SFDA).

FOLD HERE

**TECVAYLI can cause side effects such as cytokine release syndrome (CRS).** Cytokine release syndrome is a serious immune reaction that can be triggered by a variety of factors, including a range of drugs.[1]

**PATIENT'S NAME:**

_____

FOLD HERE This card has been reviewed and approved by The Saudi Food and Drug Authority (SFDA).

## Important Safety Information for Patients

**Get medical help straight away if you experience any of the following:[2]**

- Fever (38°C or higher)
- Chills
- Fast heartbeat
- Difficulty breathing
- Nausea
- Headache
- Feeling dizzy

FOLD HERE This card has been reviewed and approved by The Saudi Food and Drug Authority (SFDA).

**IMPORTANT TO REMEMBER: Stay close to the location where you received your TECVAYLI therapy for at least 2 days for daily monitoring after administration of your first three doses (usually two step-up doses and first maintenance dose).[2]** If you have **any** of the symptoms listed on this card call your doctor or seek emergency medical attention right away! These are not all the possible side effects of TECVAYLI. Tell your doctor if you have any side effect that bothers you or does not go away.

This card has been reviewed and approved by The Saudi Food and Drug Authority (SFDA).

## Treating Physician

**TREATING PHYSICIAN'S NAME:**

**TREATING PHYSICIAN'S PHONE NUMBER:**

**HOSPITAL NAME AND ADDRESS:**

**PHONE NUMBER:**

FOLD HERE

## Information for Healthcare Team to Fill In

Please give this card to your healthcare team to fill in the information and return to you.

Dates of TECVAYLI injections (step-up dosing schedule):

**STEP-UP DOSE 1**

**STEP-UP DOSE 2**

**FIRST MAINTENANCE DOSE***

*This is the first full treatment dose (1.5 mg/kg)[2]

FOLD HERE

## Important Safety Information for Healthcare Professionals

CRS, including life-threatening or fatal reactions, may occur in patients receiving TECVAYLI.[2] The majority of CRS events observed following TECVAYLI administration were Grade 1 and 2.[2] CRS may involve multiple organ systems. Assess the patient for signs and symptoms of CRS. If your patient reports any signs or symptoms as referenced on this card, please contact the patient's treating physician immediately for further information.

See Summary of Product Characteristics for full details.[2]

FOLD HERE

▼ **Adverse events reporting guidance:**
**The National Pharmacovigilance Center (NPC)**
Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa/

**For full prescribing information, please refer to the datasheet or contact Johnson & Johnson Middle East FZ-LLC (Riyadh)**
Address: Prince Muhammed Bin Abdulaziz Rd, Tower B, Level 30, Olaya towers,
Office Tel: 00966-11-4339133
Postal address: P O Box 65305 Riyadh 11556, Saudi Arabia

**To report Adverse Events/Product Complaint or any Medical Information Inquiries,please contact us at:**
Email: GCC-PV2@its.jnj.com

Hotline: 00966540015811

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.


1. Shimabukuro-Vornhagen A et al. J Immunother Cancer 2018;6(1):56.
2. TECVAYLI™ SmPC (EU), March 2023.


Please refer to the full patient leaflet for more information on Tecvayli

Scan Here


EM-136137
July 2023